Accès ouvert
2025
article
OpenAlex
Eljie Isaak Bragasin, Justin K. Cheng, Lauren Ford, Darin Poei et autres
Small cell lung cancer (SCLC) is an aggressive tumor characterized by early metastasis and resistance to treatment, making it a prime target for therapeutic investigation. The current standard of care for frontline treatment involves a combination of chemotherapeutic agents and immune checkpoint …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Anush Aram Ginosyan, Karam Ashouri, Brian Michael Hom, Brandon Ann et autres
Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) serves as a potentially curative treatment. Blinatumomab, a bispecific T-cell engager targeting CD19, has shown promise in improving B-ALL outcomes. Our aim is to evaluate the clinical impact of pretransplant blinatumomab. Methods This is a …
us
(code pays fourni par la source)
Accès ouvert
2024
conference-abstract
OpenAlex
Anush Aram Ginosyan, Karam Ashouri, Brian Michael Hom, Brandon Ann et autres
Introduction: Adult B-cell acute lymphoblastic leukemia (B-ALL) remains a challenging disease, particularly in Hispanic patients who often present with unfavorable cytogenetics. Allogeneic hematopoietic stem cell transplantation (HSCT) serves as a potentially curative treatment. Blinatumomab, a bispecific T-cell engager targeting CD19, has shown …
us
(code pays fourni par la source)
2024
article
OpenAlex
Karam Ashouri, Brian Michael Hom, Anush Aram Ginosyan, Yekta Rahimi et autres
Philadelphia chromosome (Ph)-like acute lymphoblastic leukaemia (ALL) is a high-risk subtype with a gene expression profile similar to Ph-positive ALL, due to activation of tyrosine kinase signalling. To understand the clinical implications of Ph-like ALL, this single-centre retrospective study evaluates outcomes in …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Brian Michael Hom, Karam Ashouri, Yekta Rahimi, Karen Resnick et autres
Philadelphia (Ph)-like B-cell acute lymphoblastic leukemia (B-ALL) is a high-risk subgroup of B-cell ALL. Prior studies have noted an increased prevalence of Ph-like B-ALL in Hispanic patients. Our study evaluates Ph-like B-ALL clinical/genomic features and outcomes in a predominantly Hispanic population. 1. …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Mollee Chu, Karam Ashouri, Brian Michael Hom, Jennifer D. Hwang et autres
Hematopoietic stem cell transplantation (HSCT) improves long term overall survival (OS) and disease-free survival (DFS) for intermediate and high-risk B-cell ALL. Historically, matched related donors were the only option, but with better GVHD prophylaxis, haploidentical HSCT (haplo-HSCT) is increasingly used. It may …
us
(code pays fourni par la source)
Accès ouvert
2023
conference-abstract
OpenAlex
Karam Ashouri, Brian Michael Hom, Mollee Chu, Jennifer D. Hwang et autres
Introduction: Hematopoietic stem cell transplantation (HSCT) improves long term overall survival (OS) and disease-free survival (DFS) in those with intermediate or high-risk B- cell ALL. Historically, matched related donors were the ideal choice, but with improved GVHD prophylactic regimens and supportive care, …
us
(code pays fourni par la source)
2023
conference-abstract
OpenAlex
Karam Ashouri, Brian Michael Hom, Yekta Rahimi, Karen Resnick et autres
Introduction: Philadelphia (Ph)-like B-cell acute lymphoblastic leukemia (ALL) is a high-risk subgroup of B- cell ALL with distinct genotypes, unified by a gene expression profile similar to Ph-positive ALL but lacking the BCR: ABL1 fusion. Previous studies have noted the increased prevalence …
us
(code pays fourni par la source)